General MedicationsINJECTIONGeneric
BUPIVACAINE LIPOSOME
BUPIVACAINE
Standard Dose
266MG/20ML (13.3MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview BUPIVACAINE LIPOSOME is listed in Drugs@FDA under application 214348 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient BUPIVACAINE Form and strength INJECTABLE, LIPOSOMAL;INJECTION - 266MG/20ML (13.3MG/ML) Sponsor HENGRUI PHARMA Submission history Latest submission status date: 2024-07-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview BUPIVACAINE LIPOSOME is listed in Drugs@FDA under application 214348 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BUPIVACAINE Form and strength INJECTABLE, LIPOSOMAL;INJECTION - 266MG/20ML (13.3MG/ML) Sponsor HENGRUI PHARMA Submission history Latest submission status date: 2024-07-01 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.